Dean Kirkel, MD
Hematology & Oncology · Marietta, GANPI 1740242932
Payments from drug & device makers
Across 355 payments — averaging $2530.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$219K
- Acerta Pharma LLC$183K
- Janssen Research & Development, LLC$166K
- Genentech, Inc.$56K
- Incyte Corporation$43K
- AstraZeneca$43K
- plus $188K from 31 others
What the payments were for
- Consulting fees$31,98673%
- Speaking & faculty fees$3,5508%
- Travel & lodging$4,0099%
- Food & beverage$3,8209%
- Education$2381%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 28 | $219,489 |
| Acerta Pharma LLC | 13 | $183,297 |
| Janssen Research & Development, LLC | 47 | $165,614 |
| Genentech, Inc. | 7 | $55,733 |
| Incyte Corporation | 15 | $43,497 |
| AstraZeneca(2 entities) | 15 | $42,530 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $41,017 |
| E.r. Squibb & Sons, L.L.C. | 30 | $39,190 |
| Beone Medicines USA, Inc. | 8 | $33,772 |
| Beigene USA, Inc. | 1 | $20,623 |
| Merck | 16 | $8,493 |
| Janssen Scientific Affairs, LLC | 9 | $8,033 |
| Gilead(2 entities) | 10 | $7,335 |
| Pharmacyclics LLC, An Abbvie Company | 7 | $6,124 |
| GSK | 5 | $4,100 |
| Deciphera Pharmaceuticals Inc. | 11 | $4,053 |
| Pfizer | 34 | $3,981 |
| Novartis | 9 | $3,357 |
| Puma Biotechnology, Inc. | 1 | $2,180 |
| Seagen Inc. | 22 | $1,887 |
| Karyopharm Therapeutics Inc. | 1 | $1,550 |
| Rigel Pharmaceuticals, Inc. | 1 | $1,000 |
| Beigene, Ltd. | 1 | $450 |
| Intera Oncology, Inc | 1 | $223 |
| Ipsen Biopharmaceuticals, Inc | 12 | $211 |
| AbbVie | 6 | $152 |
| Astellas Pharma US Inc | 3 | $69 |
| Johnson & Johnson(2 entities) | 5 | $60 |
| Daiichi Sankyo Inc. | 1 | $50 |
| Tersera Therapeutics LLC | 2 | $45 |
| Eisai Inc. | 2 | $39 |
| Stemline Therapeutics Inc. | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Sanofi | 1 | $15 |
| Exelixis Inc. | 1 | $12 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$898,247 in reported general payments places this provider in the 90th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 48 | $765,686 |
| JakafiRuxolitinib Phosphate | 26 | $457,795 |
| BrukinsaZanubrutinib | 31 | $332,429 |
| PomalystPomalidomide | 14 | $309,566 |
| Abiraterone Acetate | 53 | $171,407 |
| EliquisApixaban | 139 | $155,373 |
| OxbrytaVoxelotor | 12 | $146,745 |
| VenclextaVenetoclax | 13 | $68,231 |
| Fentanyl | 49 | $7,909 |
| Letrozole | 123 | $2,937 |
| Oxycodone Hcl | 128 | $1,925 |
| Exemestane | 15 | $1,796 |
| Anastrozole | 78 | $1,537 |
| ValacyclovirValacyclovir Hcl | 48 | $1,471 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 65 | $1,390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $219,489 | $765,68648 claims |
| Incyte CorporationJakafi | $43,497 | $457,79526 claims |
| Beigene USA, Inc.Brukinsa | $20,623 | $332,42931 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $39,190 | $309,56614 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $8,033 | $171,40753 claims |
| PfizerEliquis | $3,981 | $155,373139 claims |
| AbbVieVenclexta | $152 | $68,23113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Marietta
- Steven McCuneMarietta$19.5M
- Raul OyolaMarietta$2.1M
- Louis GarrotMarietta$1.3M
- Zulfiqar MalikMarietta$824K
- Gena Volas ReddMarietta$742K
- Mehmet BilenAtlanta$21.7M
- Ajay NookaAtlanta$19.3M
- Olatunji AleseAtlanta$15.5M
- Jonathon CohenAtlanta$8.7M
- Ticiana LealAtlanta$6.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.